Atossa Therapeutics, Inc. (BMV:ATOS)
Mexico · Delayed Price · Currency is MXN 16.73
0.00 (0.00%)
At close: Jul 31, 2025, 2:00 PM CST
Atossa Therapeutics Company Description
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Atossa Therapeutics, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 15 |
| CEO | Steven Quay |
Contact Details
Address: 107 Spring Street Seattle, Delaware 98104 United States | |
| Phone | 206-588-0256 |
| Website | atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | Mexican Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven Quay | Chief Executive Officer |
| Heather Rees | Chief Financial Officer |
| Michael Parks | Head of Investor Relations |